vs
OCEANEERING INTERNATIONAL INC（OII）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是OCEANEERING INTERNATIONAL INC的1.1倍（$772.1M vs $692.4M），Revvity净利率更高（12.7% vs 5.2%，领先7.5%），Revvity同比增速更快（5.9% vs 3.6%），Revvity自由现金流更多（$161.8M vs $-76.5M），过去两年Revvity的营收复合增速更高（9.0% vs 1.8%）
奥什科什国际（Oceaneering International）是一家总部位于美国得克萨斯州休斯敦的水下工程及应用技术企业，为海洋、航天及其他特殊作业场景的客户提供定制化工程服务与硬件设备，在极端环境工程领域拥有深厚的技术积累。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OII vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$692.4M
营收增速更快
RVTY
高出2.3%
3.6%
净利率更高
RVTY
高出7.5%
5.2%
自由现金流更多
RVTY
多$238.3M
$-76.5M
两年增速更快
RVTY
近两年复合增速
1.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $692.4M | $772.1M |
| 净利润 | $36.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 5.2% | 12.7% |
| 营收同比 | 3.6% | 5.9% |
| 净利润同比 | -28.3% | 3.9% |
| 每股收益（稀释后） | $0.36 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OIIRVTY
| Q1 26 | $692.4M | — | ||
| Q4 25 | $668.6M | $772.1M | ||
| Q3 25 | $742.9M | $698.9M | ||
| Q2 25 | $698.2M | $720.3M | ||
| Q1 25 | $674.5M | $664.8M | ||
| Q4 24 | $713.5M | $729.4M | ||
| Q3 24 | $679.8M | $684.0M | ||
| Q2 24 | $668.8M | $691.7M |
净利润OIIRVTY
| Q1 26 | $36.1M | — | ||
| Q4 25 | $177.7M | $98.4M | ||
| Q3 25 | $71.3M | $46.7M | ||
| Q2 25 | $54.4M | $53.9M | ||
| Q1 25 | $50.4M | $42.2M | ||
| Q4 24 | $56.1M | $94.6M | ||
| Q3 24 | $41.2M | $94.4M | ||
| Q2 24 | $35.0M | $55.4M |
毛利率OIIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.6% | 53.6% | ||
| Q2 25 | 21.3% | 54.5% | ||
| Q1 25 | 20.0% | 56.5% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 19.3% | 56.3% | ||
| Q2 24 | 18.0% | 55.7% |
营业利润率OIIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 9.8% | 14.5% | ||
| Q3 25 | 11.6% | 11.7% | ||
| Q2 25 | 11.3% | 12.6% | ||
| Q1 25 | 10.9% | 10.9% | ||
| Q4 24 | 10.9% | 16.3% | ||
| Q3 24 | 10.5% | 14.3% | ||
| Q2 24 | 9.0% | 12.4% |
净利率OIIRVTY
| Q1 26 | 5.2% | — | ||
| Q4 25 | 26.6% | 12.7% | ||
| Q3 25 | 9.6% | 6.7% | ||
| Q2 25 | 7.8% | 7.5% | ||
| Q1 25 | 7.5% | 6.4% | ||
| Q4 24 | 7.9% | 13.0% | ||
| Q3 24 | 6.1% | 13.8% | ||
| Q2 24 | 5.2% | 8.0% |
每股收益（稀释后）OIIRVTY
| Q1 26 | $0.36 | — | ||
| Q4 25 | $1.75 | $0.86 | ||
| Q3 25 | $0.71 | $0.40 | ||
| Q2 25 | $0.54 | $0.46 | ||
| Q1 25 | $0.49 | $0.35 | ||
| Q4 24 | $0.55 | $0.77 | ||
| Q3 24 | $0.40 | $0.77 | ||
| Q2 24 | $0.34 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $488.8M | — |
| 股东权益账面价值 | $1.1B | $7.3B |
| 总资产 | $2.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资OIIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $695.9M | $919.9M | ||
| Q3 25 | $7.0M | $931.4M | ||
| Q2 25 | $7.0M | $991.8M | ||
| Q1 25 | $7.0M | $1.1B | ||
| Q4 24 | $504.5M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务OIIRVTY
| Q1 26 | $488.8M | — | ||
| Q4 25 | $487.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $482.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益OIIRVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $907.7M | $7.4B | ||
| Q2 25 | $842.1M | $7.6B | ||
| Q1 25 | $773.1M | $7.6B | ||
| Q4 24 | $714.3M | $7.7B | ||
| Q3 24 | $698.0M | $7.9B | ||
| Q2 24 | $651.0M | $7.9B |
总资产OIIRVTY
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.7B | $12.2B | ||
| Q3 25 | $2.5B | $12.1B | ||
| Q2 25 | $2.3B | $12.4B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.3B | $13.4B |
负债/权益比OIIRVTY
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.67× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-76.5M | $161.8M |
| 自由现金流率自由现金流/营收 | -11.1% | 21.0% |
| 资本支出强度资本支出/营收 | 2.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $238.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流OIIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $221.1M | $182.0M | ||
| Q3 25 | $101.3M | $138.5M | ||
| Q2 25 | $77.2M | $134.3M | ||
| Q1 25 | $-80.7M | $128.2M | ||
| Q4 24 | $128.4M | $174.2M | ||
| Q3 24 | $91.9M | $147.9M | ||
| Q2 24 | $52.6M | $158.6M |
自由现金流OIIRVTY
| Q1 26 | $-76.5M | — | ||
| Q4 25 | $190.7M | $161.8M | ||
| Q3 25 | $77.0M | $120.0M | ||
| Q2 25 | $46.9M | $115.5M | ||
| Q1 25 | $-106.8M | $112.2M | ||
| Q4 24 | $94.5M | $149.8M | ||
| Q3 24 | $67.0M | $125.6M | ||
| Q2 24 | $29.8M | $136.6M |
自由现金流率OIIRVTY
| Q1 26 | -11.1% | — | ||
| Q4 25 | 28.5% | 21.0% | ||
| Q3 25 | 10.4% | 17.2% | ||
| Q2 25 | 6.7% | 16.0% | ||
| Q1 25 | -15.8% | 16.9% | ||
| Q4 24 | 13.2% | 20.5% | ||
| Q3 24 | 9.9% | 18.4% | ||
| Q2 24 | 4.5% | 19.7% |
资本支出强度OIIRVTY
| Q1 26 | 2.5% | — | ||
| Q4 25 | 4.6% | 2.6% | ||
| Q3 25 | 3.3% | 2.6% | ||
| Q2 25 | 4.3% | 2.6% | ||
| Q1 25 | 3.9% | 2.4% | ||
| Q4 24 | 4.7% | 3.4% | ||
| Q3 24 | 3.7% | 3.3% | ||
| Q2 24 | 3.4% | 3.2% |
现金转化率OIIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | 1.85× | ||
| Q3 25 | 1.42× | 2.97× | ||
| Q2 25 | 1.42× | 2.49× | ||
| Q1 25 | -1.60× | 3.03× | ||
| Q4 24 | 2.29× | 1.84× | ||
| Q3 24 | 2.23× | 1.57× | ||
| Q2 24 | 1.50× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OII
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
